FORTRESS BIOTECH INC. - COMMON STOCK

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

06 1 2025 08:00:04 提供 Nasdaq GlobeNewswire

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

14 11 2024 16:10:31 提供 Nasdaq GlobeNewswire

Fortress Biotech to Participate in October 2024 Investor Conferences

26 9 2024 08:30:50 提供 Nasdaq GlobeNewswire

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

20 9 2024 08:30:35 提供 Nasdaq GlobeNewswire

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

04 9 2024 08:30:11 提供 Nasdaq GlobeNewswire

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

13 8 2024 16:05:46 提供 Nasdaq GlobeNewswire

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

25 7 2024 08:30:53 提供 Nasdaq GlobeNewswire

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

05 7 2024 16:05:00 提供 Nasdaq GlobeNewswire

Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase

16 5 2024 08:00:38 提供 Nasdaq GlobeNewswire

Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

15 5 2024 16:15:29 提供 Nasdaq GlobeNewswire

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

14 5 2024 08:30:00 提供 Nasdaq GlobeNewswire

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

28 3 2024 16:05:13 提供 Nasdaq GlobeNewswire